InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
0.00%
)
US TECH 100
19,210.00
(
0.24%
)
Dow Jones
39,118.86
(
0.00%
)
Brent Oil
85.48
(
0.43%
)
Bitcoin
62,806.04
(
0.33%
)
Post# of 252444
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151628

Friday, 11/02/2012 12:37:54 PM

Friday, November 02, 2012 12:37:54 PM

Post# of 252444

Copaxone is still holding more than 40% of MS drugs market share.

What’s impressive is that Copaxone’s US share of patient Rx’s for MS has not changed to a significant degree from the launch of Gilenya or the uptake in Tysabri from JC-testing. Rather, Copaxone’s US share has remained at or near 40% for the past few years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up